Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1143

1.

Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.

Gershenwald JE, Mansfield PF, Lee JE, Ross MI.

Ann Surg Oncol. 2000 Mar;7(2):160-5.

PMID:
10761797
2.

Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.

Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF.

J Am Acad Dermatol. 2001 May;44(5):762-6.

PMID:
11312421
3.

Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases.

Landi G, Polverelli M, Moscatelli G, Morelli R, Landi C, Fiscelli O, Erbazzi A.

J Eur Acad Dermatol Venereol. 2000 Jan;14(1):35-45. Review.

PMID:
10877250
4.

The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, Vuylsteke RJ, Meijer S.

Cancer. 2001 Jun 15;91(12):2401-8.

PMID:
11413531
5.

Significance of dual-basin drainage in patients with truncal melanoma undergoing sentinel lymph node biopsy.

Jacobs IA, Chang CK, Salti GI.

J Am Acad Dermatol. 2003 Oct;49(4):615-9.

PMID:
14512905
6.

Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status.

Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG.

Ann Surg Oncol. 2002 Aug;9(7):637-45.

PMID:
12167577
7.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
8.

[Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].

Arens A, Osinga J, Schwipper V, Schober O, Tilkorn H, Liebau J.

Chirurg. 2003 Jul;74(7):665-70. German.

PMID:
12883795
9.

Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.

Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K, Pehamberger H, Diem E.

Br J Cancer. 2005 Feb 28;92(4):662-7.

10.

Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma.

Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF, O'Brien JC, Kuhn JA.

Am J Surg. 2003 Dec;186(6):675-81.

PMID:
14672778
11.

Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?

Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2009 Dec 15;115(24):5752-60. doi: 10.1002/cncr.24660.

12.

Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.

Gannon CJ, Rousseau DL Jr, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE.

Cancer. 2006 Dec 1;107(11):2647-52.

13.

Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?

Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR.

Cancer. 2010 Mar 15;116(6):1535-44. doi: 10.1002/cncr.24895.

14.

Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W.

Ann Surg Oncol. 2006 Dec;13(12):1655-63.

PMID:
17016755
15.

Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.

Roka F, Mastan P, Binder M, Okamoto I, Mittlboeck M, Horvat R, Pehamberger H, Diem E.

Eur J Surg Oncol. 2008 Jan;34(1):82-8.

PMID:
17360144
16.

Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases.

Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Fraile M, Alastrué A, Ferrándiz C.

Dermatol Surg. 2005 Nov;31(11 Pt 1):1385-93.

PMID:
16416605
17.

Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Rousseau DL Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE.

Ann Surg Oncol. 2003 Jun;10(5):569-74.

PMID:
12794025
18.

Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma.

Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR 3rd, Leong SP.

Arch Dermatol. 1998 Aug;134(8):983-7.

PMID:
9722728
19.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
20.

Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

Macripò G, Quaglino P, Caliendo V, Ronco AM, Soltani S, Giacone E, Pau S, Fierro MT, Bernengo MG.

Melanoma Res. 2004 Apr;14(2):S9-12.

PMID:
15057050

Supplemental Content

Support Center